Abstract
Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification.
In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.Keywords: Hypertension, aortic valve stenosis, antihypertensive drugs, ACEi/ARB, diuretics, alpa- beta-blockers, calcium channel blockers, vasodilators.
Current Pharmaceutical Design
Title:Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis
Volume: 23 Issue: 8
Author(s): Paolo Poggio*, Gianluca Folesani, Giuseppe M. Raffa, Paola Songia, Vincenzo Valenti, Veronika Myasoedova and Alessandro Parolari
Affiliation:
- Laboratory of Biochemical Cardiology Unit for the Study of Aortic, Valvular and Coronary Pathologies Centro Cardiologico Monzino, IRCCS Via Carlo Parea 4, 20138 Milan,Italy
Keywords: Hypertension, aortic valve stenosis, antihypertensive drugs, ACEi/ARB, diuretics, alpa- beta-blockers, calcium channel blockers, vasodilators.
Abstract: Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. Severe aortic stenosis affects ≈2% to 5% of adults age > 65 years. Systemic hypertension is a frequent comorbidity in patients with AVS and is coexistent for a longer period of time before AVS is treated. Essential systemic hypertension, per se, plays an important role in the creation of lesions on the aortic side of the valve, the region of higher exposure to tension stress. The subsequent endothelial defect represents the principal site of inflammatory process and oxidative stress, leading to aortic sclerosis and calcification.
In this review, we want to describe the pharmacological features of the common antihypertensive drugs, analysing the recent literature, in order to achieve useful and updated information about the best treatment of systemic hypertension in patients with concomitant severe aortic stenosis.Export Options
About this article
Cite this article as:
Poggio Paolo*, Folesani Gianluca, Raffa M. Giuseppe, Songia Paola, Valenti Vincenzo, Myasoedova Veronika and Parolari Alessandro, Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis, Current Pharmaceutical Design 2017; 23 (8) . https://dx.doi.org/10.2174/1381612823666161123144534
DOI https://dx.doi.org/10.2174/1381612823666161123144534 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pulmonary Hemorrhage in Patients with Systemic Lupus Erythematosus
Current Respiratory Medicine Reviews Value of Sodium-Glucose Co-Transporter 2 Inhibitor Versus Traditional Medication in Microalbuminuric Diabetic Patients
Current Diabetes Reviews Nitric Oxide Donors as Potential Drugs for the Treatment of Vascular Diseases Due to Endothelium Dysfunction
Current Pharmaceutical Design Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews An UPLC Method for Determination of Geraniin in Rat Plasma and its Application to Pharmacokinetic Studies
Current Pharmaceutical Analysis Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Clinical Implications of Recent Insights into the Structural Biology of Beta2 Adrenoceptors
Current Drug Targets Rational Targeting of Peroxisome Proliferating Activated Receptor Subtypes
Current Medicinal Chemistry Elucidation of the Mechanisms and Molecular Targets of Qishen Yiqi Formula for the Treatment of Pulmonary Arterial Hypertension using a Bioinformatics/Network Topology-based Strategy
Combinatorial Chemistry & High Throughput Screening Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews Disease Outcome, Alexithymia and Depression are Differently Associated with Serum IL-18 Levels in Acute Stroke
Current Neurovascular Research Gum-Chewing and Headache: An Underestimated Trigger of Headache Pain in Migraineurs?
CNS & Neurological Disorders - Drug Targets Update on COX-2 Selective Inhibitors: Chemical Classification, Side Effects and their Use in Cancers and Neuronal Diseases
Current Topics in Medicinal Chemistry Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial: Natural Products as the Integral Part of the Therapy?
Current Pharmaceutical Design The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design